ReviewStem cells translational medicine2018
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
Review in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Stem cell-based therapies in pediatric disorders: translational advances, unresolved challenges, and future horizons.Stem cell research & therapy · 2026Review
- Unproven stem cell-based interventions marketed as treatments in Panama: An urgent call for enforcement actions.Stem cell reports · 2026Article
- Review
- Mesenchymal Stem Cell Based-Regenerative Therapy in Atherosclerosis: an Updated Review.Current cardiology reports · 2025Review
- Confronting medical grifting: Fraudulent and unproven products and interventions in apheresis, transfusion and biotherapies.British journal of haematology · 2025Review
- Myths and Realities about the Private Sector Stem Cell Industry in Malaysia.Asian bioethics review · 2025Article
- Intramedullary Neural Stem Cell Transplantation in Spinal Cord Injury: Timing, Targets, and Techniques.Korean journal of neurotrauma · 2025Review
- Stem cell therapy for peripheral nerve injury: illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
- The evolution and ongoing challenge of unproven cell-based interventions.Stem cells translational medicine · 2024Review
- Optimization of methods for intrasplenic administration of human amniotic epithelial cells in order to perform safe and effective cell-based therapy for liver diseases.Stem cell reviews and reports · 2024Article
- US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.Cytotherapy · 2024Article
- Public awareness and understanding of stem cell treatments available in Saudi Arabia and their trust in hospitals and research centers involved in stem cell research-a cross sectional study.Frontiers in public health · 2024Article
- Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group.Journal of pain research · 2024Review
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Knowledge about stem cell sources and obstacles in donation of bone marrow and peripheral blood stem cells: a cross-sectional survey from Ha'il city to track the prospects of regenerative medicine in Saudi Arabia.Journal of pharmaceutical health care and sciences · 2023Article
- Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism.Emerging infectious diseases · 2023Review
- Stem cell therapy for traumatic brachial plexus injury.Acta neurochirurgica · 2023Article
- Aging and obesity prime the methylome and transcriptome of adipose stem cells for disease and dysfunction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Adipose-Derived Mesenchymal Stromal Cells in Basic Research and Clinical Applications.International journal of molecular sciences · 2023Review
- Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology.NAM perspectives · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public's willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the "stem cell tourism" phenomenon. Stem Cells Translational Medicine 2018;1-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.